Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.

Nature communications - 19 Nov 2021

Qiu Bin, Guo Wei, Zhang Fan, Lv Fang, Ji Ying, Peng Yue, Chen Xiaoxi, Bao Hua, Xu Yang, Shao Yang, Tan Fengwei, Xue Qi, Gao Shugeng, He Jie

Abstract excerpt

Accurately evaluating minimal residual disease (MRD) could facilitate early intervention and personalized adjuvant therapies. Here, using ultradeep targeted next-generation sequencing (NGS), we evaluate the clinical utility of circulating tumor DNA (ctDNA) for dynamic recurrence risk and adjuvant chemotherapy (ACT) benefit prediction in resected non-small cell lung cancer (NSCLC). Both postsurgical and post-ACT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Clinical Decision-Making

Share to Disease-Free Survival

Share to Neoplasm Recurrence, Local

Share to Neoplasm, Residual

Share to Pneumonectomy

Source

Open in PubMed Open full text

Identifiers

PMID: 34799585
DOI: 10.1038/s41467-021-27022-z
PMCID: PMC8605017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.PMID 34799585Read ↗

Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).Semantic proximity Read ↗

Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.Semantic proximity Read ↗

Molecular Residual Disease in Non‐Small Cell Lung Cancer: Technology or Patient Outcomes?Semantic proximity Read ↗

Characterization of clinical risk factors for enhanced molecular residual disease monitoring in resected early-stage non-small cell lung cancer.Semantic proximity Read ↗

Prognostic potential of circulating tumor DNA detection at different time periods in resectable non-small cell lung cancer: Evidence from a meta-analysis.Semantic proximity Read ↗

Dynamic Surveillance of Minimal Residual Disease via a Tumor-Informed Circulating Tumor DNA Assay for Outcome Prediction in Small-Cell Lung Cancer: A Prospective Pilot StudySemantic proximity Read ↗

Prognostic value of preoperative ctDNA and pathological venous invasion for recurrence in EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Real-World Utilization and Performance of Circulating Tumor DNA Monitoring to Predict Recurrence in Solid TumorsSemantic proximity Read ↗

Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer.Semantic proximity Read ↗

Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA FragmentomicsSemantic proximity Read ↗

Individualized dynamic methylation-based analysis of cell-free DNA in postoperative monitoring of lung cancerSemantic proximity Read ↗

Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.